Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT00347919 · ClinicalTrials.gov registry record · Phase 2

Pazopanib Plus Lapatinib Compared To Lapatinib Alone In Subjects With Advanced Or Metastatic Breast Cancer

A Phase 2 study of Neoplasms, Breast, sponsored by GlaxoSmithKline.

Completed
Registry status
Phase 2
Development phase
189
Enrollment target
20
Study locations

NCT00347919 is a Phase 2 study of Neoplasms, Breast that has completed, run by GlaxoSmithKline. The registered enrollment target is 189 participants, below the 1,047-participant average among 9 other Neoplasms, Breast trials with a reported enrollment target (82% lower). The trial reports 20 study locations across 9 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT00347919, a Phase 2 study of Neoplasms, Breast, has completed, sponsored by GlaxoSmithKline.

COMPLETED
Registry status
Phase 2
Development phase
189 participants
Enrollment target
20
Study locations

Study Summary

This study is being conducted to compare the efficacy and safety of pazopanib in combination with lapatinib with that of lapatinib alone in subjects with locally advanced or metastatic breast cancer whose tumors overexpress the ErbB2 protein.

Conditions Studied

Neoplasms, Breast

Interventions

  • DRUG pazopanib (GW786034) 400 mg
  • DRUG lapatinib (GW572016) 1500 mg
  • DRUG lapatinib (GW572016) 1000 mg
  • DRUG pazopanib (GW786034) 800 mg

Study Locations (20)

California

  • GSK Investigational Site - Alhambra
  • GSK Investigational Site - Bakersfield
  • GSK Investigational Site - Fullerton
  • GSK Investigational Site - Long Beach
  • GSK Investigational Site - Los Angeles
  • GSK Investigational Site - Northridge
  • GSK Investigational Site - Oxnard
  • GSK Investigational Site - Redondo Beach
  • GSK Investigational Site - Santa Barbara
  • GSK Investigational Site - Santa Maria

Texas

  • GSK Investigational Site - Dallas
  • GSK Investigational Site - Lubbock
  • GSK Investigational Site - San Antonio

Arkansas

  • GSK Investigational Site - Jonesboro

Indiana

  • GSK Investigational Site - Indianapolis

Louisiana

  • GSK Investigational Site - Metairie

Nevada

  • GSK Investigational Site - Henderson

New York

  • GSK Investigational Site - The Bronx

Ohio

  • GSK Investigational Site - Akron

Trial Details

FieldValue
Enrollment Target 189 participants
Start Date 2006-07
Est. Completion 2015-03
Phase Phase 2

Sponsor

GlaxoSmithKline

1,345 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT00347919

The ClinicalTrials.gov registry entry for NCT00347919 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 189 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 1,047-participant average among 9 other Neoplasms, Breast trials with a reported enrollment target (82% lower). The listed sponsor is GlaxoSmithKline, which has 1,345 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Neoplasms, Breast appearing as the primary indexed condition, and to 4 interventions - of which pazopanib (GW786034) 400 mg is the first listed.

NCT00347919 reports 20 study locations spanning 9 distinct geographic areas - top geographies include California, Texas, Arkansas.

Frequently Asked Questions

What is clinical trial NCT00347919 about?

NCT00347919 is a clinical study titled "Pazopanib Plus Lapatinib Compared To Lapatinib Alone In Subjects With Advanced Or Metastatic Breast Cancer". This study is being conducted to compare the efficacy and safety of pazopanib in combination with lapatinib with that of lapatinib alone in subjects with locally advanced or metastatic breast cancer whose tumors overexpress the ErbB2 protein.

What is the current status of trial NCT00347919?

This trial is currently completed. It is a Phase 2 study. The enrollment target is 189 participants. The study started on 2006-07. Estimated completion is 2015-03.

What conditions does trial NCT00347919 study?

This clinical trial studies the following conditions: Neoplasms, Breast.

What interventions are being tested in trial NCT00347919?

The interventions under investigation include: pazopanib (GW786034) 400 mg (DRUG), lapatinib (GW572016) 1500 mg (DRUG), lapatinib (GW572016) 1000 mg (DRUG), pazopanib (GW786034) 800 mg (DRUG).

Who is sponsoring clinical trial NCT00347919?

This trial is sponsored by GlaxoSmithKline, which has 1,345 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT00347919 being conducted?

This trial has 20 study locations across Arkansas, California, Indiana, Louisiana, Nevada. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Neoplasms, Breast

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Neoplasms, Breast

All registered trials for this condition

Arkansas

All trials with a study site in Arkansas

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.